Affiliation:
1. Department of Maternal and Child Health, Xiangya School of Public Health Central South University Changsha China
2. The Affiliated Women and Children's Hospital of Xiamen University Xiamen China
3. Liver Disease Center Hunan Children's Hospital Changsha China
Abstract
AbstractThis study aimed to assess the predictive capacity of emerging serological markers, serum HBV RNA and HBcrAg, for HBeAg seroconversion in children with HBeAg‐positive chronic hepatitis B (CHB). Treatment‐naïve HBeAg‐positive CHB children who admitted to the Liver Disease Center of Hunan Children's Hospital between April 2021 and September 2022 and received treatment with the combined entecavir and interferon‐alpha treatment were recruited. Serum HBV RNA and HBcrAg were measured at baseline and Weeks 12, 24, and 48 of treatment. Our study showed that serum HBV RNA (HR = 0.71, 95% CI: 0.56–0.91, p = 0.006), HBcrAg (HR = 0.60, 95% CI: 0.43–0.84, p = 0.003), and HBsAg (HR = 0.49, 95%CI: 0.36–0.69, p < 0.001) at Week 12 were independent predictors of HBeAg seroconversion. ROC curve analysis presented that serum HBV RNA decline value (ΔHBV RNA) at Week 36 and HBcrAg decline value (ΔHBcrAg) at Week 12 (AUC = 0.871, p = 0.003 and AUC = 0.810, p = 0.003, respectively) could effectively predict HBeAg seroconversion. Furthermore, the optimal critical values were determined and the children with ΔHBV RNA > 3.759 log10 copies/mL at Week 36 or ΔHBcrAg >0.350 log10 U/mL at Week 12 more likely to achieve HBeAg seroconversion. The serum HBV RNA and HBcrAg provide new insights into the treatment of CHB in children. Early assessment of serum HBV RNA and HBcrAg during treatment can assist clinical decision‐making and optimize individualized therapeutic approaches.